A checkpoint combination extends survival in advanced melanoma
Five-year data suggest durable responses for a third of patients, but toxicity remains the trade-off.
Clara Whitfield · 1 November 2026
Clinical trials, drug development and research news
Five-year data suggest durable responses for a third of patients, but toxicity remains the trade-off.
Clara Whitfield · 1 November 2026
New data reopen the debate over who benefits from anti-amyloid antibodies.
Clara Whitfield · 31 October 2026
Curative treatments are arriving faster than payers can price them.
Clara Whitfield · 30 October 2026
Beyond weight loss, cardiovascular benefits are reshaping prescribing.
Clara Whitfield · 29 October 2026
The Briefing
One email. The week's readouts, approvals and research, explained without hype.
From obesity to Alzheimer's, the trials that could move markets.
Clara Whitfield · 26 October 2026
Five-year data suggest durable responses for a third of patients, but toxicity remains the trade-off.
Clara Whitfield · 1 November 2026
Curative treatments are arriving faster than payers can price them.
Clara Whitfield · 30 October 2026
Beyond weight loss, cardiovascular benefits are reshaping prescribing.
Clara Whitfield · 29 October 2026
New data reopen the debate over who benefits from anti-amyloid antibodies.
Clara Whitfield · 31 October 2026
New rules demand confirmatory trials be underway before approval.
Clara Whitfield · 28 October 2026
A practical guide to registries, eligibility and the questions to ask.
Clara Whitfield · 27 October 2026
Sponsors must now submit diversity action plans for pivotal studies.
Clara Whitfield · 25 October 2026